
Sign up to save your podcasts
Or


Fibrodysplasia ossificans progressiva (FOP) is a severely disabling myopathy in which extraskeletal bone forms and accumulates over time within muscles and soft tissues.1,2 Here’s what we know so far about the mechanisms of heterotopic ossification in patients with FOP.
References:
© 2025 Ipsen Biopharmaceuticals Inc. All rights reserved. ALLSC-US-001927 | August 2025
In this short video, Dr. Shelia Morrison explains how she introduces parents to myopia management by emphasizing that today's treatment options—like MiSight® 1 day—can both correct vision and slow myopia progression during critical growth periods. She highlights the importance of early intervention and presents daily disposable lenses as a safe, effective solution for active children.
Listen to Dr. Eric Ritchey explain how he introduces MiSight® 1 day to parents—highlighting its safety, comfort, and dual benefits—and emphasizes the importance of daily disposables for hygiene and the long-term eye health advantages of managing myopia early in children.
Dr. Ariel Cerenzie shares quick tips on how she communicates the urgency of myopia progression to parents and introduces MiSight® 1 day as a proactive solution. She explains that the lenses not only correct vision but also therapeutically slow myopia progression, offering a meaningful way to protect a child’s long-term eye health.
Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4
References:
USA-CRP-24-0038 July 2025
In this short video, Dr. Ashley Tucker shares how she talks to parents about myopia management, emphasizing that myopia is more than just blurry vision; it’s a progressive condition that can lead to serious eye health risks. She introduces MiSight® 1 day as a dual-purpose option that not only corrects vision, but also helps slow the progression of myopia in age-appropriate children.
Myopia is more than blurred vision; it's a chronic condition requiring lifelong attention that could affect up to five billion people by 2050. In response to this growing crisis, the World Council of Optometry (WCO) has issued standard-of-care guidelines built around three pillars: Mitigation, Measurement, and Management. Tune in to learn about this evidence-based framework and how it can help you turn routine visits into proactive prevention opportunities.
Reference:
World Council of Optometry. The Standard of Care For Myopia Management by Optometrists. Accessed July 21, 2025. https://myopia.worldcouncilofoptometry.info/standard-of-care/
Many eye care professionals and parents still believe children must wait until their teenage years to wear contact lenses, but as Dr. Jeffrey Walline explains, modern daily disposable lenses offer improved safety, comfort, and ease of use, making them a viable option for children as young as 7 or 8. And beyond the clinical benefits of slowing myopia progression and preserving long-term eye health, contact lenses have also been shown to improve children’s self-esteem. Learn more with Dr. Walline, Associate Dean of Academic Affairs at The Ohio State University College of Optometry.
Many parents hesitate to allow young children to wear contact lenses, fearing poor hygiene or increased risk of infection. But evidence shows that kids between the ages of 7 and 12 are not at higher risk than teens; in fact, they actually have fewer complications than college-age wearers, and long-term studies reveal no difference in eye health between those fit with contact lenses in childhood versus adolescence. Here to talk about the safety of contact lenses for myopic children is Dr. Jeffrey Walline, Associate Dean of Academic Affairs at The Ohio State University College of Optometry.
Pediatric sickle cell disease treatment, particularly the use of hydroxyurea, NSAIDs, and opioids, has evolved in response to clinical guidelines and regulatory shifts, but gaps still remain in how children receive essential medications. Joining Dr. Charles Turck to discuss these national prescribing trends, disparities in care, and the implications of evolving treatment guidelines for this population is Dr. Abiodun Ologunowa. Dr. Ologunowa is a doctoral candidate and research assistant in the Department of Pharmacy Practice and Clinical Research at the University of Rhode Island College of Pharmacy.